Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia.
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multiple PI3K isoforms may provide greater efficacy. The development of compounds targeting multiple PI3K isoforms (α, β, δ, and γ) in CLL cells, in vitro, resulted in sustained inhibition of BCR signalling but with enhanced cytotoxicity and the potential for improve clinical responses. This review summarises the progress of PI3K inhibitor development and describes the rationale and potential for targeting multiple PI3K isoforms.
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, SO16 6YD, United Kingdom.
Matthew D
MD
Blunt
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, SO16 6YD, United Kingdom.
Andrew J
AJ
Steele
CLL; Duvelisib; Idelalisib; PI3K